Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD
- 1 January 2022
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 22 (1), 117-124
- https://doi.org/10.2174/1871530321666210225110140
Abstract
Background and Objectives: Non-alcoholic fatty liver disease (NAFLD) is associated with inflammation and subsequent increase in cardiovascular risk. Because of its widespread presence and distribution, invasive diagnostic procedures (i.e., liver biopsy) are reserved for a limited number of subjects. With liver ultrasound, Fatty liver index (FLI) and fibrosis-4 (FIB-4) scores non-invasively assess liver steatosis and fibrosis. We aimed to evaluate the changes in inflammatory markers and FLI/FIB-4 scores in non-obese metformin-treated type 2 diabetes patients (T2DM) with NAFLD. Methods: All subjects underwent abdominal ultrasound aiming for NAFLD stratification (grade 1 to 3 according to its severity). Metabolic parameters (morning glycaemia, HbA1C, lipids, liver function tests) and serum inflammatory markers (C-reactive protein, ferritin, and nitric oxide), and FLI/FIB-4 are calculated. Results: FLI score and ultrasound NAFLD grades correlated (p<0.05). We observed a significant correlation between the levels of ferritin and C-reactive protein (CRP) (p<0.05), and the FLI (p<0.05). Body weight (BW) (p<0.05), waist circumference (WC) (p<0.05), the levels of HbA1c (p<0.05), transferrin (p<0.05), insulin (p<0.05), and FLI score (p<0.05) significantly differed between groups defined by the severity of NAFLD. Conclusion: This pilot study suggests that the serum inflammatory markers at the average normal values point to the sufficiency of metformin-single therapy in inflammation control in non-obese T2DM patients with NAFLD.Keywords
Funding Information
- Ministry of Education, Science and Technological Development of the Republic of Serbia, (451-03-9/2021-14/ 200017)
This publication has 33 references indexed in Scilit:
- Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndromeThe Lancet Diabetes & Endocrinology, 2014
- Imaging of non alcoholic fatty liver disease: A road less travelledIndian Journal of Endocrinology and Metabolism, 2013
- Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patientsLiver International, 2011
- Noninvasive assessment of liver fibrosisHepatology, 2010
- Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort StudyThe American Journal of Gastroenterology, 2010
- Nitrate and nitrite in biology, nutrition and therapeuticsNature Chemical Biology, 2009
- Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus NoninvasiveSeminars in Liver Disease, 2008
- In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver diseaseHepatology, 2006
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005